What the Pelacarsen Trial Result Means

On September 4, 2026 Novartis announced that pelacarsen failed to meet its primary endpoint in the Phase III Lp(a)HORIZON trial, a result that challenges the idea that lowering lipoprotein(a) will automatically cut cardiovascular events. The trial's primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, and it was tested in two co-primary populations defined by Lp(a) thresholds. While genetics and epidemiology have long linked high Lp(a) to greater heart risk, the HORIZON outcome shows that biological lowering of Lp(a) does not necessarily produce the expected clinical benefit in an already-treated population.

Lp(a)HORIZON enrolled 8,323 patients with elevated Lp(a), randomized to pelacarsen 80 mg monthly or placebo on top of guideline-directed therapies, and the companies reported that pelacarsen substantially lowered Lp(a) levels but did not reduce major adverse cardiovascular events in the overall population. The study has been described as randomized, double-blind and placebo-controlled, and Ionis noted that pelacarsen demonstrated an acceptable safety profile; full Lp(a)HORIZON data will be presented at an upcoming medical congress. Trial protocol included two co-primary populations, Lp(a) ≥70 mg/dL and Lp(a) ≥90 mg/dL, which were assessed separately and together.

Although the topline result is disappointing, it will be scrutinized closely because it is the first definitive cardiovascular outcomes test of targeted Lp(a) lowering; researchers and drug developers must now examine subgroup data, event rates and the magnitude of Lp(a) reduction before drawing broad conclusions. If future analyses were to show benefit in a defined subgroup or with different dosing, the field could pivot rather than abandon the approach; nevertheless, the HORIZON outcome will reshape plans for new trials and for how clinicians think about treating inherited lipid risk.